Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Heather A Jacene

Showing results (41-50 of 76) with videos related to

Pageof 8
Sort By:
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|June 2, 2007
Efficacy of preoperative combined 18-fluorodeoxyglucose positron emission tomography and computed tomography for assessing primary rectal cancer response to neoadjuvant therapyGenevieve B Melton, William C Lavely, Heather A Jacene, et al.
Journal of the American Academy of Dermatology|November 7, 2012
Positron emission tomography/computed tomography imaging in Merkel cell carcinoma: a study of 270 scans in 97 patients at the Dana-Farber/Brigham and Women's Cancer CenterElena B Hawryluk, Kevin N O'Regan, Niall Sheehy, et al.
International Journal of Radiation Oncology, Biology, Physics|May 22, 2012
Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PETLia M Halasz, Heather A Jacene, Paul J Catalano, et al.
Blood|August 31, 2016
Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapyBruce D Cheson, Stephen Ansell, Larry Schwartz, et al.
Clinical Genitourinary Cancer|September 22, 2016
Radium-223 Use in Clinical Practice and Variables Associated With Completion of TherapyRana R McKay, Susanna Jacobus, Matthew Fiorillo, et al.
Breast Cancer Research and Treatment|April 23, 2020
Discrepancy between FDG-PET/CT and contrast-enhanced CT in the staging of patients with inflammatory breast cancer: implications for treatment planningHeather A Jacene, Pamela J DiPiro, Jennifer Bellon, et al.
Annals of Surgical Oncology|March 21, 2015
Inflammatory Breast Cancer: Patterns of Failure and the Case for Aggressive Locoregional ManagementLaura E G Warren, Hao Guo, Meredith M Regan, et al.
Breast Cancer Research and Treatment|April 21, 2015
Inflammatory breast cancer and development of brain metastases: risk factors and outcomesLaura E G Warren, Hao Guo, Meredith M Regan, et al.
American Journal of Surgery|September 22, 2022
Higher SUV<sub>max</sub> on FDG-PET is associated with shorter survival in adrenocortical carcinomaSean M Wrenn, Alessandra L Moore, Hina J Shah, et al.
Journal of Nuclear Medicine Technology|August 5, 2018
Guidance on <sup>177</sup>Lu-DOTATATE Peptide Receptor Radionuclide Therapy from the Experience of a Single Nuclear Medicine DivisionAmanda Abbott, Christopher G Sakellis, Eric Andersen, et al.
Pageof 8

Showing results (41-50 of 76) with videos related to

Sort By:
Pageof 8
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|June 2, 2007
Efficacy of preoperative combined 18-fluorodeoxyglucose positron emission tomography and computed tomography for assessing primary rectal cancer response to neoadjuvant therapyGenevieve B Melton, William C Lavely, Heather A Jacene, et al.
Journal of the American Academy of Dermatology|November 7, 2012
Positron emission tomography/computed tomography imaging in Merkel cell carcinoma: a study of 270 scans in 97 patients at the Dana-Farber/Brigham and Women's Cancer CenterElena B Hawryluk, Kevin N O'Regan, Niall Sheehy, et al.
International Journal of Radiation Oncology, Biology, Physics|May 22, 2012
Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PETLia M Halasz, Heather A Jacene, Paul J Catalano, et al.
Blood|August 31, 2016
Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapyBruce D Cheson, Stephen Ansell, Larry Schwartz, et al.
Clinical Genitourinary Cancer|September 22, 2016
Radium-223 Use in Clinical Practice and Variables Associated With Completion of TherapyRana R McKay, Susanna Jacobus, Matthew Fiorillo, et al.
Breast Cancer Research and Treatment|April 23, 2020
Discrepancy between FDG-PET/CT and contrast-enhanced CT in the staging of patients with inflammatory breast cancer: implications for treatment planningHeather A Jacene, Pamela J DiPiro, Jennifer Bellon, et al.
Annals of Surgical Oncology|March 21, 2015
Inflammatory Breast Cancer: Patterns of Failure and the Case for Aggressive Locoregional ManagementLaura E G Warren, Hao Guo, Meredith M Regan, et al.
Breast Cancer Research and Treatment|April 21, 2015
Inflammatory breast cancer and development of brain metastases: risk factors and outcomesLaura E G Warren, Hao Guo, Meredith M Regan, et al.
American Journal of Surgery|September 22, 2022
Higher SUV<sub>max</sub> on FDG-PET is associated with shorter survival in adrenocortical carcinomaSean M Wrenn, Alessandra L Moore, Hina J Shah, et al.
Journal of Nuclear Medicine Technology|August 5, 2018
Guidance on <sup>177</sup>Lu-DOTATATE Peptide Receptor Radionuclide Therapy from the Experience of a Single Nuclear Medicine DivisionAmanda Abbott, Christopher G Sakellis, Eric Andersen, et al.
Pageof 8